Onderneming Paradigm Biopharmaceuticals Limited
Aandelen
PAR
AU000000PAR5
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,285 AUD | +1,79% | +11,76% | -32,94% |
Vakgebied
Verkoop per activiteit
AUD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Pharmaceutical Drugs
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | -40,98% |
Verkoop per regio
AUD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Australia
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | -40,98% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Rennie
CEO | Chief Executive Officer | - | 02-05-14 |
Abby Macnish
DFI | Director of Finance/CFO | - | 30-08-22 |
Jill Forrest
CTO | Chief Tech/Sci/R&D Officer | - | - |
Melanie Duiker
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-17 |
Ravi Krishnan
CTO | Chief Tech/Sci/R&D Officer | - | - |
Donna Skerrett
CTO | Chief Tech/Sci/R&D Officer | - | 01-09-19 |
Simon White
IRC | Investor Relations Contact | - | 01-01-20 |
Corporate Officer/Principal | - | - | |
Karla Knower
LAW | General Counsel | - | - |
Corporate Officer/Principal | - | 13-10-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Donna Skerrett
CTO | Chief Tech/Sci/R&D Officer | - | 01-09-19 |
Paul Rennie
CEO | Chief Executive Officer | - | 02-05-14 |
Amos Meltzer
BRD | Director/Board Member | 58 | 09-12-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 351 495 841 | 304 232 313 ( 86,55 %) | 0 | 86,55 % |
Bedrijfsgegevens
Paradigm Biopharmaceuticals Ltd.
500 Collins Street Level 15
3000, Melbourne
+
http://www.paradigmbiopharma.comSector
Herzieningen van WPA
Winst van het jaar - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-32,94% | 64,96 mln. | |
+29,77% | 49,18 mld. | |
+1,00% | 42,11 mld. | |
+50,47% | 40,37 mld. | |
-5,26% | 28,85 mld. | |
+13,68% | 26,09 mld. | |
-22,99% | 18,71 mld. | |
+8,22% | 13,26 mld. | |
+32,41% | 12,32 mld. | |
-1,62% | 11,99 mld. |